JPRN-jRCT2080222370未知1 期
A Phase I Clinical Study of BBI608 Administered with Paclitaxel in Patients with Previously treated Unresectable/Recurrent Gastric Cancer
试验速览
- 阶段
- 1 期
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •- Signed, written informed consent
- •- Unresectable/recurrent gastric cancer which was histologically confirmed as an adenocarcinoma (including adenocarcinomas of the gastroesophageal junction)
- •- Disease progression after one or more chemotherapy regimens OR recurrence within 6 months of completion of postoperative adjuvant therapy for unresectable/recurrent gastric cancer
- •- Maintained normal organ functions
- •- ECOG performance status of 0 or 1
排除标准
- •- Patients with any known untreated brain metastases
研究者
相似试验
未知
1 期
A Phase I Clinical Study of BBI608 in Adult Patients with Advanced Solid TumorsAdvanced solid tumorsJPRN-jRCT2080222106Sumitomo Dainippon Pharma Co., Ltd.18
已完成
1 期
A Phase Ib/II Study of BBI608 in Combination with Pembrolizumab in Patients with Metastatic Colorectal Cancermetastatic colorectal cancerJPRN-UMIN000023149ational Cancer Center Hospital East95
已完成
1 期
Clinical pharmacology study of BBI608JPRN-jRCT2080225351Sumitomo Dainippon Pharma. Co,.Ltd.70
进行中（未招募）
1 期
The aim of this study is to see how well an investigational drug (called BBI-608) works when it is given in combination with a standard anticancer treatment for people with advanced colon or rectal cancer.EUCTR2016-001627-31-BEBoston Biomedical, Inc.1,250
进行中（未招募）
1 期
The aim of this study is to see how well an investigational drug (called BBI-608) works when it is given in combination with a standard anticancer treatment for people with advanced colon or rectal cancer.Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic (Stage IV).MedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2016-001627-31-NLSumitomo Dainippon Pharma Oncology, Inc.1,250